BI 1015550

Drug Profile

BI 1015550

Latest Information Update: 24 May 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 24 May 2016 No recent reports on development identified - Phase-I for Undefined indication in Germany (PO)
  • 11 Apr 2013 Boehringer Ingelheim initiates enrolment in a phase I trial in Healthy volunteers in Germany (NCT01835899)
  • 30 Sep 2012 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Germany (NCT01594515)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top